Corcept Therapeutics (CORT) stock soared 35% after the FDA approved its ovarian cancer drug, Relacorilant (Lifyoril), ahead of schedule. The approval covers the drug for use with chemotherapy to treat adults with platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer.